Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EBITDA (2016 - 2025)

Regenxbio has reported EBITDA over the past 12 years, most recently at -$67.2 million for Q4 2025.

  • Quarterly results put EBITDA at -$67.2 million for Q4 2025, down 30.85% from a year ago — trailing twelve months through Dec 2025 was -$193.8 million (up 13.24% YoY), and the annual figure for FY2025 was -$193.8 million, up 13.24%.
  • EBITDA for Q4 2025 was -$67.2 million at Regenxbio, down from -$61.8 million in the prior quarter.
  • Over the last five years, EBITDA for RGNX hit a ceiling of $292.7 million in Q4 2021 and a floor of -$86.1 million in Q1 2022.
  • Median EBITDA over the past 5 years was -$59.5 million (2023), compared with a mean of -$41.9 million.
  • Peak annual rise in EBITDA hit 724.66% in 2021, while the deepest fall reached 803.7% in 2021.
  • Regenxbio's EBITDA stood at $292.7 million in 2021, then crashed by 119.5% to -$57.1 million in 2022, then decreased by 4.95% to -$59.9 million in 2023, then increased by 14.29% to -$51.3 million in 2024, then crashed by 30.85% to -$67.2 million in 2025.
  • The last three reported values for EBITDA were -$67.2 million (Q4 2025), -$61.8 million (Q3 2025), and -$70.9 million (Q2 2025) per Business Quant data.